

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED**  
**北京同仁堂國藥有限公司**  
*(Incorporated in Hong Kong with limited liability)*  
**(Stock Code: 3613)**

**APPOINTMENT OF EXECUTIVE DIRECTOR,  
THE CHAIRMAN OF THE BOARD AND  
AUTHORISED REPRESENTATIVE**

**APPOINTMENT OF EXECUTIVE DIRECTOR, THE CHAIRMAN OF THE BOARD AND  
AUTHORISED REPRESENTATIVE**

The board of directors (the “**Board**”) of Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) is pleased to announce that Mr. Gu Hai Ou (“**Mr. Gu**”) has been appointed as an executive director of the Company, the chairman of the Board and authorised representative of the Company under Rule 3.05 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of the Hong Kong Limited (the “**Stock Exchange**”) with effect from 13 December 2023.

The biographical details of Mr. Gu are set out as follows:

**Gu Hai Ou**, aged 58, is currently the vice general manager and member of Standing Committee of Party Committee of China Beijing Tong Ren Tang Group Co., Ltd., and the vice president of the China Association of Traditional Chinese Medicine, as well as an executive director and the chairman of board of directors of Tong Ren Tang Technologies Co. Ltd. (“**Tong Ren Tang Technologies**”, a company listed on the Stock Exchange, (stock code: 1666), and a controlling shareholder of the Company) since 11 June 2019. He has tendered his resignation as the executive director and the chairman of board of directors of Tong Ren Tang Technologies on 13 December 2023, that will take effect upon the new executive director being elected at the general meeting of Tong Ren Tang Technologies to be held. Mr. Gu joined Beijing Tong Ren Tang Group in 1991 and was formerly the vice general manager, the chief engineer, director, the chairman of board of directors of Beijing Tong Ren Tang Company Limited. Mr. Gu graduated from the Shanghai University of Traditional Chinese Medicine in July 1986 with a bachelor’s degree, and obtained a master’s degree in medical science from Beijing University of Chinese Medicine in July 1991. Mr. Gu holds the title of researcher and is also a licensed pharmacist.

Mr. Gu shall hold office until the next following annual general meeting of the Company after his appointment and if re-elected by the shareholders of the Company (the “**Shareholders**”) thereat, will be subject to retirement by rotation and re-election at annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. A service contract (the “**Contract**”) was entered into between the Company and Mr. Gu on 13 December 2023 for a period of three years. Pursuant to the Contract, Mr. Gu will not receive any director’s fee as an executive director of the Company.

As at the date of this announcement, Mr. Gu does not have any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

As at the date of this announcement, save as disclosed above, Mr. Gu has not held any directorship in any Hong Kong or overseas listed companies in the last three years. Save as disclosed above, Mr. Gu does not have any relationship with any director, senior management or substantial or controlling shareholder(s) (as defined in the Listing Rules) of the Company nor does he hold any other position with the Company or any of its subsidiaries.

Save as disclosed above, Mr. Gu has confirmed that there is no other information relating to him that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters which need to be brought to the attention of the Shareholders in connection with the aforesaid appointment.

The Board would like to extend its warmest welcome to Mr. Gu for joining the Board.

#### **RE-COMPLIANCE WITH RULE 3.05 OF THE LISTING RULES**

Reference is made to the announcement of the Company dated 12 September 2023 in relation to the resignation of the authorised representative of the Company and non-compliance with Rule 3.05 of Listing Rules. Following the above-mentioned appointment of Mr. Gu as the authorised representative of the Company, the Company has two authorised representatives and complies with Rule 3.05 of the Listing Rules.

By order of the Board  
**Beijing Tong Ren Tang**  
**Chinese Medicine Company Limited**  
**Gu Hai Ou**  
*Chairman*

Hong Kong, 13 December 2023

As at the date of this announcement, the composition of the Board is as follows:

***Executive Directors:***

Mr. Gu Hai Ou (*Chairman*)  
Mr. Yu Jin  
Mr. Chen Fei

***Independent Non-executive Directors:***

Mr. Tsang Yok Sing, Jasper  
Mr. Xu Hong Xi  
Mr. Chan Ngai Chi

***Non-executive Director:***

Ms. Feng Li